Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 43: 2189-2190, 1997;
This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (25)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Taylor, P. J.
Right arrow Articles by Pond, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Taylor, P. J.
Right arrow Articles by Pond, S. M.
Related Collections
Right arrow Drug Monitoring and Toxicology
(Clinical Chemistry. 1997;43:2189-2190.)
© 1997 American Association for Clinical Chemistry, Inc.

Technical Briefs

Improved Therapeutic Drug Monitoring of Tacrolimus (FK506) by Tandem Mass Spectrometry

Paul J. Taylor1,2,a, Nicholas S. Hogan2, Stephen V. Lynch3, Anthony G. Johnson1,2 and Susan M. Pond1,2

1 Dept. of Clin. Pharmacol., First Floor Lions Clin. Res. Bldg.,
2 Univ. of Queensland Dept. of Med., and
3 Univ. of Queensland Dept. of Surgery, Princess Alexandra Hosp., Ipswich Rd., Brisbane, QLD, Australia, 4102;
a author for correspondence: fax 61-7-3240-5031; e-mail Ptaylor@gpo.pa.uq.edu.au

The immunosuppressant drug tacrolimus (FK506), which exhibits 50–100 times the potency of cyclosporin A, is proving to be highly effective in preventing rejection in solid-organ transplantation (1). However, because of a narrow therapeutic range, variable pharmacokinetics, and potential drug interactions, continual therapeutic drug monitoring (TDM) of tacrolimus is essential (2). Recently, we published a report that detailed the development of a specific, sensitive method for quantification of tacrolimus concentrations in blood (3). This methodology, which utilizes HPLC in combination with tandem mass spectrometry (LC-MS2), was found to have greater specificity, lower detection limits, and a more rapid turnaround time than existing immunoassays. These attributes make this methodology ideal for TDM of tacrolimus.

Since our initial report, several modifications that have further improved the assay for TDM have been implemented. The use of a 100 x 2 mm C8 column (rather than a 30 x 2 mm C4 . . . [Full Text of this Article]


Acknowledgments


References




The following articles in journals at HighWire Press have cited this article:


Home page
 J. Am. Soc. Nephrol.Home page
B. L. KASISKE, M. A. VAZQUEZ, W. E. HARMON, R. S. BROWN, G. M. DANOVITCH, R. S. GASTON, D. ROTH, J. D. SCANDLING JR., and G. G. SINGER
Recommendations for the Outpatient Surveillance of Renal Transplant Recipients
J. Am. Soc. Nephrol., October 1, 2000; 11 (90001): S1 - S86.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. L. Cogill, P. J. Taylor, I. S. Westley, R. G. Morris, S. V. Lynch, and A. G. Johnson
Evaluation of the tacrolimus II microparticle enzyme immunoassay (MEIA II) in liver and renal transplant recipients
Clin. Chem., September 1, 1998; 44(9): 1942 - 1946.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Association for Clinical Chemistry.